title: Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
abstract: Iron supplementation in hemodialysis patients is fundamental to erythropoiesis, but may cause harmful effects. We measured oxidative stress using labile plasma iron (LPI) after parenteral iron replacement in chronic hemodialysis patients. Intravenous iron saccharate (100 mg) was administered in patients undergoing chronic hemodialysis (N = 20). LPI was measured by an oxidant-sensitive fluorescent probe at the beginning of dialysis session (T0), at 10 min (T1), 20 min (T2), and 30 min (T3) after the infusion of iron and at the subsequent session; P < 0.05 was significant. The LPI values were significantly raised according to the time of administration and were transitory: -0.02 +/- 0.20 micromol/L at the beginning of the first session, 0.01 +/- 0.26 micromol/L at T0, 0.03 +/- 0.23 micromol/L at T1, 0.09 +/- 0.28 micromol/L at T2, 0.18 +/- 0.52 micromol/L at T3, and -0.02 +/- 0.16 micromol/L (P = 0.001 to 0.041) at the beginning of the second session. The LPI level in patients without iron supplementation was -0.06 +/- 0.16 micromol/L. Correlations of LPI according to time were T1, T2, and T3 vs. serum iron (P = 0.01, P = 0.007, and P = 0.0025, respectively), and T2 and T3 vs. transferrin saturation (P = 0.001 and P = 0.0003, respectively). LPI generation after intravenous saccharate administration is time-dependent and transitorily detected during hemodialysis. The LPI increment had a positive correlation to iron and transferrin saturation.
authors.affiliation: Dialysis Center, Hospital Israelita Albert Einstein, University of São Paulo, São Paulo, Brazil. erikabr@uol.com.br
authors.forename: Erika B
authors.initials: EB
authors.lastname: Rangel
authors.forename: Breno P
authors.initials: BP
authors.lastname: Espósito
authors.forename: Fabiana D
authors.initials: FD
authors.lastname: Carneiro
authors.forename: Ana Cláudia
authors.initials: AC
authors.lastname: Mallet
authors.forename: Ana Cristina C
authors.initials: AC
authors.lastname: Matos
authors.forename: Maria Cláudia C
authors.initials: MC
authors.lastname: Andreoli
authors.forename: Nádia K
authors.initials: NK
authors.lastname: Guimarães-Souza
authors.forename: Bento Fc
authors.initials: BF
authors.lastname: Santos
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D013997:Time Factors
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid